TITLE

Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes

AUTHOR(S)
FERRARA, ASSIAMIRA; LEWIS, JAMES D.; QUESENBERRY JR., CHARLES P.; PENG, TIFFANY; STROM, BRIAN L.; VAN DEN EEDEN, STEPHEN K.; EHRLICH, SAMANTHA F.; HABEL, LAUREL M.
PUB. DATE
April 2011
SOURCE
Diabetes Care;Apr2011, Vol. 34 Issue 4, p923
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--To explore whether treatment with pioglitazone was associated with risk of incident cancer at the 10 most common sites (prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma [NHL], pancreas, kidney/renal pelvis, rectal, and melanoma). RESEARCH DESIGN AND METHODS--A cohort study of 252,467 patients aged ≥40 years from the Kaiser Permanente Northern California Diabetes Registry was conducted. All prescriptions for diabetes medications were identified by pharmacy records. Cox proportional hazards models were used to examine the association between risk of incident cancer and ever use, duration, dose, and time since initiation of pioglitazone (modeled as time-dependent variables). RESULTS--In models adjusted for age, sex, year of cohort entry, race/ethnicity, income, smoking, glycemic control, diabetes duration, creatinine levels, congestive heart failure, and use of other diabetes medications, the hazard ratio (HR) for each cancer associated with ever use of pioglitazone ranged from 0.7 to 1.3, with all 95% CIs including 1.0. There was a suggestion of an increased risk of melanoma (HR 1.3 [95% CI 0.9-2.0]) and NHL (1.3 [1.0-1.8]) and a decreased risk of kidney/renal pelvis cancers (0.7 [0.4-1.1]) associated with ever use of pioglitazone. These associations were unaltered with increasing dose, duration, or time since first use. CONCLUSIONS--We found no clear evidence of an association between use of pioglitazone and risk of the incident cancers examined. Because the maximum duration of follow-up was fewer than 6 years after the initiation of pioglitazone, longer-term studies are needed.
ACCESSION #
60705079

 

Related Articles

  • Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. LEWIS, JAMES D.; FERRARA, ASSIAMIRA; PENG, TIFFANY; HEDDERSON, MONIQUE; BILKER, WARREN B.; QUESENBERRY JR., CHARLES P.; VAUGHN, DAVID J.; NESSEL, LISA; SELBY, JOSEPH; STROM, BRIAN L. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p916 

    OBJECTIVE--Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients...

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Improved Postprandial Glycemic Control With Insulin Aspart. Lindholm, Anders; McEwen, John; Riis, Anders P. // Diabetes Care;May99, Vol. 22 Issue 5, p801 

    Presents information on a study which compared the postprandial serum glucose control after administration of insulin aspart, a rapid-acting insulin analog, with that of unmodified human insulin in patients with type one diabetes. Research design and methods; Results; Conclusions.

  • Proceedings of the National Academy of Sciences: Licorice root found to contain anti-diabetic substance.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article focuses on a research, in which researchers have discovered an anti-diabetic substance in the amorfrutin class of natural substances from Licorice root.

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • Research Shows Diabetes Drug May Also Cut Cancer Risks.  // Heart Advisor;Feb2014, Vol. 17 Issue 2, p3 

    The article reports on the findings of a study led by Cleveland Clinic Foundation on two commonly used diabetes drugs, which reveals the potential of insulin sensitizers to reduce the risk of cancer while reducing diabetes symptoms. According to the study, insulin sensitizers lower blood glucose...

  • Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer. Bodmer, Michael; Meier, Christian; Krähenbühl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1304 

    OBJECTIVE -- To evaluate whether use of oral hypoglycemic agents is associated with an altered breast cancer risk in women. RESEARCH DESIGN AND METHODS-- Using the U.K.-based General Practice Research Database, we conducted a nested case-control analysis among 22,621 female users of oral...

  • New Users of Metformin Are at Low Risk of Incident Cancer. Libby, Gillian; Donnelly, Louise A.; Donnan, Peter T.; Alessi, Dario R.; Morris, Andrew D.; Evans, Josie M. M. // Diabetes Care;Sep2009, Vol. 32 Issue 9, p1620 

    OBJECTIVE -- The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that...

  • Diabetes and Cancer.  // Current Medical Literature: Diabetes;2012, Vol. 29 Issue 2, p60 

    The article discusses several studies on the connection between diabetes and cancer. One study examined the link between type 2 diabetes and breast cancer risk. Two studies analyzed how either glitazone use is associated an overall reduced risk of malignant tumors in a Chinese population, or use...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics